Product Description
Estramustine is used to treat prostate cancer that has worsened or has spread to other parts of the body. Estramustine is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a608046.html)
Mechanisms of Action: MAPs Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Belgium | Bosnia | Brazil | Canada | Chile | Croatia | Czech | Denmark | France | Germany | Greece | Hungary | India | Ireland | Italy | Korea | Luxembourg | Mexico | Morocco | New Zealand | Peru | Portugal | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|